Chemotherapy at first diagnosis of advanced prostate cancer - revolution or evolution?: Findings from a British Uro-oncology Group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer
Chemotherapy at first diagnosis of advanced prostate cancer - revolution or evolution?: Findings from a British Uro-oncology Group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer
This survey reports oncologists' attitudes towards a major change in practice in the standard of care for men with newly diagnosed advanced prostate cancer in the UK. The survey highlighted the complexities surrounding the clinical implementation of the data from these studies, including changes in referral pathways, with the early involvement of oncologists in such patients' care, increases in workloads for oncologists and chemotherapy units and the need for national approval for re-imbursement of these treatments.
bug, castrate sensitive, chemotherapy, docetaxel, metastatic, prostate cancer
376–385
Davda, R.
fbef60a5-674e-4f83-b0c0-4878ab4ecad7
Hughes, S.
d246ca0a-9850-46c6-8f64-a11fa8e51085
Jones, R.
9d9f872b-9caa-442a-aef0-c6f14826ef55
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Troup, J.
27e5d9f6-796d-4f85-af89-4ef6c10bbfbd
Payne, H.
700deed4-1c2c-4227-873b-b700498507f6
June 2016
Davda, R.
fbef60a5-674e-4f83-b0c0-4878ab4ecad7
Hughes, S.
d246ca0a-9850-46c6-8f64-a11fa8e51085
Jones, R.
9d9f872b-9caa-442a-aef0-c6f14826ef55
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Troup, J.
27e5d9f6-796d-4f85-af89-4ef6c10bbfbd
Payne, H.
700deed4-1c2c-4227-873b-b700498507f6
Davda, R., Hughes, S., Jones, R., Crabb, S.J., Troup, J. and Payne, H.
(2016)
Chemotherapy at first diagnosis of advanced prostate cancer - revolution or evolution?: Findings from a British Uro-oncology Group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer.
Clinical Oncology, 28 (6), .
(doi:10.1016/j.clon.2016.01.006).
(PMID:26874654)
Abstract
This survey reports oncologists' attitudes towards a major change in practice in the standard of care for men with newly diagnosed advanced prostate cancer in the UK. The survey highlighted the complexities surrounding the clinical implementation of the data from these studies, including changes in referral pathways, with the early involvement of oncologists in such patients' care, increases in workloads for oncologists and chemotherapy units and the need for national approval for re-imbursement of these treatments.
This record has no associated files available for download.
More information
Accepted/In Press date: 15 December 2015
e-pub ahead of print date: 11 February 2016
Published date: June 2016
Keywords:
bug, castrate sensitive, chemotherapy, docetaxel, metastatic, prostate cancer
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 388535
URI: http://eprints.soton.ac.uk/id/eprint/388535
ISSN: 0936-6555
PURE UUID: b385a77e-1814-488d-b601-d5d0a6269584
Catalogue record
Date deposited: 29 Feb 2016 10:37
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
R. Davda
Author:
S. Hughes
Author:
R. Jones
Author:
J. Troup
Author:
H. Payne
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics